triazoles has been researched along with cilostazol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bajaj, M; Birnbaum, Y; Castillo, AC; Ling, S; Perez-Polo, JR; Qian, J; Ye, H; Ye, Y | 1 |
| Huisamen, B | 1 |
2 other study(ies) available for triazoles and cilostazol
| Article | Year |
|---|---|
Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus.
Topics: Animals; Blood Glucose; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Immunoblotting; Lipids; Lipoxins; Male; Membrane Proteins; Mice; Myocardial Infarction; Myocardium; Phosphodiesterase 3 Inhibitors; PTEN Phosphohydrolase; Tetrazoles; Triazoles | 2012 |
Cyclic AMP and PKA: how can a lot of good come from the potentially bad? : editorial to: "phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus" by Y
Topics: Animals; Cilostazol; Cyclic AMP; Diabetes Mellitus, Type 2; Male; Myocardial Infarction; Phosphodiesterase 3 Inhibitors; Tetrazoles; Triazoles | 2012 |